Literature DB >> 21899994

Danshen-Gegen decoction protects against hypoxia/reoxygenation-induced apoptosis by inhibiting mitochondrial permeability transition via the redox-sensitive ERK/Nrf2 and PKCε/mKATP pathways in H9c2 cardiomyocytes.

Po Yee Chiu1, Hoi Yan Leung, Pou Kuan Leong, Na Chen, Limin Zhou, Zhong Zuo, Philip Y Lam, Kam Ming Ko.   

Abstract

Danshen-Gegen (DG) Decoction, an herbal formulation containing Radix Salviae miltiorrhizae and Radix Puerariae lobatae, has been used for the treatment of coronary artery disease in Chinese medicine. In the present study, the involvement of ERK- and PKCε-mediated pathways in the cytoprotection against apoptosis afforded by DG pretreatment was investigated in H9c2 cardiomyocytes. Pretreatment with a methanol extract of aqueous DG decoction protected against hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. The cytoprotection was associated the enhancement of cellular reduced glutathione and a reduced sensitivity to Ca(2+)-induced mitochondrial permeability transition. DG extract increased the production of cytochrome P-450 (CYP)-dependent reactive oxygen species (ROS) in H9c2 cardiomyocytes, which was accompanied by the concomitant activation of ERK1/2 and PKCε. The DG-induced ERK1/2 activation was followed by the translocation of Nrf2 from the cytosol to the mitochondria accompanied by an increase in the expression of glutathione-related antioxidant proteins. In addition, the increased expression of hemeoxygenase-1 was associated with the activation of Akt and BAD, indicative of anti-apoptotic activity. In conclusion, DG treatment activated both ERK/Nrf2 and PKCε pathways, presumably by ROS arising from CYP-catalyzed processes, with resultant inhibition of hypoxia/reoxygenation-induced apoptosis immediately after DG treatment or even after an extended time interval following DG treatment.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899994     DOI: 10.1016/j.phymed.2011.07.002

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  5 in total

Review 1.  Cardiovascular Disease, Mitochondria, and Traditional Chinese Medicine.

Authors:  Jie Wang; Fei Lin; Li-Li Guo; Xing-Jiang Xiong; Xun Fan
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

2.  The modified Yi qi decoction protects cardiac ischemia-reperfusion induced injury in rats.

Authors:  Xiao Yu; Xiao-Dong Zhao; Rong-Qi Bao; Jia-Yu Yu; Guo-Xing Zhang; Jing-Wei Chen
Journal:  BMC Complement Altern Med       Date:  2017-06-21       Impact factor: 3.659

3.  Network Pharmacology Analysis and Experimental Verification Strategies Reveal the Action Mechanism of Danshen Decoction in Treating Ischemic Cardiomyopathy.

Authors:  Mengnan Liu; Gang Yuan; Gang Luo; Xin Guo; Mingtai Chen; Huayi Yang; Fan He; Tingfu Yang; Xinyue Zhang; Qibiao Wu; Hua Zhou; Sijin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-02       Impact factor: 2.650

4.  Demographic and Prescribing Patterns of Chinese Herbal Products for Individualized Therapy for Ischemic Heart Disease in Taiwan: Population-Based Study.

Authors:  Yu-Chiang Hung; Ying-Jung Tseng; Wen-Long Hu; Hsuan-Ju Chen; Tsai-Chung Li; Pei-Yuan Tsai; Hsin-Ping Chen; Meng-Hsuan Huang; Fang-Yen Su
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

Review 5.  Ten years' research on a cardiovascular tonic: a comprehensive approach-from quality control and mechanisms of action to clinical trial.

Authors:  Ping-Chung Leung; Chi-Man Koon; Clara Bik-San Lau; Ping Chook; William King-Fai Cheng; Kwok-Pui Fung; Timothy Chi-Yui Kwok; Kam-Sang Woo
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-12       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.